Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
21
Recruiting, any sponsor type, condition "narcolepsy"
By trial status
The same filters, counted in each status. Pick one to switch.
21 trials
Showing 1 to 21, recently updated first.
- A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaPivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT06767683 · 786 participants (planned) · Start Jan 27, 2025 · Primary completion Jun 2030
Drug: ALKS 2680, 4mg; ALKS 2680, 6mg and 4 more · For: Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic Hypersomnia
Sites: Cullman, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 50 sites in all
- A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)Pivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT07540897 · 150 participants (planned) · Start Aug 13, 2026 · Primary completion Jun 2027
Drug: ALKS 2680 Dose 1; ALKS 2680 Dose 2 and 1 more · For: Narcolepsy Type 1
Sites: Scottsdale, Arizona; Brandon, Florida; Miami, Florida · 53 sites in all
- A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2Pivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT07502443 · 176 participants (planned) · Start Apr 22, 2026 · Primary completion May 2027
Drug: ALKS 2680 Dose 1; ALKS 2680 Dose 2 and 2 more · For: Narcolepsy Type 2
Sites: Cullman, Alabama; Phoenix, Arizona; Los Angeles, California · 61 sites in all
- A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1Pivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT07455383 · 150 participants (planned) · Start Apr 6, 2026 · Primary completion May 2027
Drug: ALKS 2680 Dose 1; ALKS 2680 Dose 2 and 1 more · For: Narcolepsy Type 1
Sites: Cullman, Alabama; Phoenix, Arizona; Tucson, Arizona · 66 sites in all
- A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IHPivotal-lookingRecruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT07625280 · 120 participants (planned) · Start Jul 9, 2026 · Primary completion Dec 23, 2027
Drug: Xywav · For: Narcolepsy; Idiopathic Hypersomnia
Sites: Birmingham, Alabama; Cullman, Alabama; Daphne, Alabama · 27 sites in all
- A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With NarcolepsyPivotal-lookingRecruiting
Harmony Biosciences Management, Inc.Industry
NCT07675135 · 258 participants (planned) · Start Jun 4, 2026 · Primary completion Oct 2027
Drug: HBS-301 · For: EDS; Cataplexy; Fatigue and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Peoria, Arizona · 64 sites in all
- A Study of TAK-360 in People With Narcolepsy or Idiopathic HypersomniaPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07646678 · 500 participants (planned) · Start Jun 11, 2026 · Primary completion Jun 15, 2031
Drug: TAK-360; Placebo · For: Idiopathic Hypersomnia; Narcolepsy Type 1; Narcolepsy Type 2
Sites: Chula Vista, California; Santa Ana, California; Colorado Springs, Colorado · 33 sites in all
- A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of HypersomnolencePivotal-lookingRecruiting
Centessa Pharmaceuticals (UK) LimitedIndustry
NCT07598708 · 222 participants (planned) · Start May 29, 2026 · Primary completion Sep 30, 2027
Drug: cleminorexton; Placebo · For: Narcolepsy Type 1; Narcolepsy Type 2
Sites: Birmingham, Alabama; Colorado Springs, Colorado; Brandon, Florida · 26 sites in all
Xijing HospitalAcademic, hospital or other
NCT07871006 · 20 participants (planned) · Start Oct 1, 2025 · Primary completion Jun 30, 2027
Drug: ofatumumab 20mg · For: Narcolepsy Type 1 (NT1)
Sites: Xi'an, China
TakedaTakeda (TAK)
NCT06952699 · 88 participants (planned) · Start May 6, 2025 · Primary completion Nov 30, 2026
Drug: TAK-360 · For: Narcolepsy Type 2
Sites: Auburn, Alabama; Chandler, Arizona; Chula Vista, California · 52 sites in all
Axsome Therapeutics, Inc.Industry
NCT06413420 · 1,731 participants (planned) · Start Jul 31, 2019 · Primary completion Sep 2029
Drug: Sunosi (solriamfetol); Other prescription wake-promoting medications or stimulants · For: Narcolepsy; Obstructive Sleep Apnea; Pregnant Women and Their Offspring
Sites: Morrisville, North Carolina; Wilmington, North Carolina
- A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE)Pivotal-lookingRecruiting
Suven Life Sciences LimitedIndustry
NCT07540364 · 240 participants (planned) · Start Sep 2026 · Primary completion Nov 19, 2027
Drug: Samelisant; Placebo · For: Narcolepsy
Sites: Columbia, South Carolina
- A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have NarcolepsyPivotal-lookingRecruiting
H. Lundbeck A/SIndustry
NCT07613710 · 104 participants (planned) · Start Jun 13, 2025 · Primary completion Feb 9, 2027
Drug: Lu AH69593; Placebo · For: Narcolepsy
Sites: Helsinki, Finland; Turku, Finland
TakedaTakeda (TAK)
NCT07633301 · 92 participants (planned) · Start Jun 4, 2026 · Primary completion Nov 28, 2027
Drug: TAK-360; Placebo · For: Narcolepsy Type 1
Sites: Redwood City, California; Miami, Florida; Cincinnati, Ohio · 18 sites in all
- WAKIX® (Pitolisant) Pregnancy RegistryRecruiting
Harmony Biosciences Management, Inc.Industry
NCT05536011 · 1,329 participants (planned) · Start Aug 24, 2021 · Primary completion Jun 30, 2030
Drug: Pitolisant; Comparator Products · For: Pregnancy Related; Narcolepsy
Sites: Morrisville, North Carolina
- A Phase 1, First-in-human Study of VX-433Pivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07584434 · 118 participants (planned) · Start May 21, 2026 · Primary completion Mar 5, 2027
Drug: VX-433; Placebo and 2 more · For: Narcolepsy Type 1 (NT1)
Sites: Salt Lake City, Utah
Eisai Inc.Eisai
NCT07493265 · 64 participants (planned) · Start Mar 26, 2026 · Primary completion Feb 14, 2027
Drug: E2086; Placebo · For: Narcolepsy
Sites: Santa Ana, California; Brandon, Florida; Medley, Florida · 57 sites in all
- A Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaPivotal-lookingRecruiting
Centessa Pharmaceuticals (UK) LimitedIndustry
NCT06752668 · 248 participants (planned) · Start Dec 23, 2024 · Primary completion Dec 2026
Drug: ORX750; Placebo · For: Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic Hypersomnia
Sites: Auburn, Alabama; Chandler, Arizona; Scottsdale, Arizona · 37 sites in all
- A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaRecruiting
Centessa Pharmaceuticals (UK) LimitedIndustry
NCT07096674 · 90 participants (planned) · Start Aug 12, 2025 · Primary completion Apr 30, 2026
Drug: ORX750; ORX750 and 1 more · For: Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic Hypersomnia
Sites: Auburn, Alabama; Santa Ana, California; Miami, Florida · 24 sites in all
- A Study of TAK-861 for the Treatment of Selected Central Hypersomnia ConditionsPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT05816382 · 500 participants (planned) · Start Apr 5, 2023 · Primary completion Feb 28, 2028
Drug: TAK-861 · For: Narcolepsy Type 1
Sites: Birmingham, Alabama; Redwood City, California; Santa Ana, California · 52 sites in all
Stanford UniversityAcademic, hospital or other
NCT06809803 · 36 participants (planned) · Start Oct 27, 2025 · Primary completion Jun 2027
Drug: Extended-release sodium oxybate; Non-extended-release oxybates · For: Narcolepsy Type 1 (NT 1)
Sites: Redwood City, California
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.